



Accepted Abstracts for CROI 2018

Protocol	Title	Authors	Presentation Type
<i>Times and Dates TBA</i>			
PROMISE 1077BF/FF	Similar clinical outcomes between formula and breastfeeding women in PROMISE	Hoffman RM, Angelidou K, Brummel SS, Saidi F, Violari A, Dula D, Mave V, Fairlie L, Theron G, Kamateeka M, Chipato T, Klingman K, Chakhtoura N, Currier JS, Fowler MG, for the PROMISE 1077BF/FF team	Oral presentation
PROMISE 1077HS	Predictors of virologic failure in postpartum women on ART in PROMISE 1077HS	Hoffman RM, Warshaw M, Amico KR, Pilotto JH, Masheto G, Achalapong J, Machado ES, Chokephaibulkit K, Duarte G, Coletti A, Browning R, Chakhtoura N, Klingman K, and Currier JS, for the PROMISE 1077HS team	Poster presentation
PROMISE 1077BF	PROMISE trial: Results of continued vs discontinued ART after end of breastfeeding	Taha TE, Brummel S, Angelidou K, Fowler MG, Flynn PM, Mukuzunga C, Dula DE, Owor M, Moodley D, Chipato T, Loftis AJ, Chakhtoura N, McCarthy K, Currier JS, for the IMPAACT PROMISE Study Team	Oral presentation
PROMISE 1077BF/FF/HS	HIV-1 viral rebound and safety outcomes of postpartum treatment interruption in women	Le CN, Britto P, Brummel S, Hoffman RM, Flynn PM, Taha TE, Coletti A, Fowler MG, Klingman KL, McIntyre JA, Li JZ, Currier JS	Poster presentation
NWCS 121	Infant HIV vaccination: relationship to childhood vaccines and maternal antibodies	Itell H, McGuire E, Chen M, Muresan P, Permar S, and Fouda G	Poster presentation
NWCS 116/P1025	Markers of preterm delivery in HIV+ women; Role of protease inhibitors and vitamin D	Weinberg A, Huo Y, Kacanek D, Patel K, Watts H, Wara D, Klawitter J, Christians U, for IMPAACT Team P1025	Poster presentation
P1104s	African multi-site 2-year study of neurocognition in HIV infected/affected children	Boivin MJ, Chernoff M, Laughton B, Zimmer B, Joyce C, Barlow-Mosha L, Bwakura-Dangarembizi M, Ratswana M, Fairlie L, Kamthunzi P, McCarthy K, Jean-Philippe P, Violari A, Cotton M, Palumbo P	Poster presentation



Accepted Abstracts for CROI 2018

Protocol	Title	Authors	Presentation Type
<i>Times and Dates TBA</i>			
P1101	Phase I/II study of a raltegravir-containing regimen in HIV-infected children with TB	Meyers T, Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Hovind L, Sise T, Tepler H, Dittmer S, Fairlie L, Hesselning AC, Cotton MF	Poster presentation
P1106	Pharmacokinetics and safety of lopinavir/ritonavir solution in HIV-infected newborns	Bekker A, Hanan N, Cababasay M, Wang J, Nakwa F, Smith E, Moye J, Violari A, Cotton M, Wiesner L, Norman J, Fourie B, Capparelli EV, Mirochnick M, IMPAACT P1106 team	Poster presentation
NWCS 612/ P1072	Intestinal damage and inflammation in perinatally HIV-1-infected African infants	Koay WA, Lindsey JC, Uprety P, Weinberg A, Levin MJ, Bwakura-Dangarembizi M, Persaud D	Poster presentation
Lab	A two-dimensional approach to analyzing broadly neutralizing antibody combinations	Webb NE, Severeid CM, Tobin NH, Aldrovandi GM	Poster presentation
P1090	Etravirine pharmacokinetics in treatment-experienced HIV-infected children ≥ 12 mos to < 6 yrs	MacBrayne CE, Rutstein R, Yogev R, Wiznia A, Fairlie L, Graham B, Alvero C, Moye J, Townley E, Crauwels H, Woot de Trixhe X, Tambuyzer L, Vanveggel S, Opsomer M, Kiser JJ	Poster presentation
Lab	Pregnancy associated vaginal proteome alterations linked to HIV acquisition risk	Zuend CF, Tobin N, Birse K, Noël-Romas L, Vera T, Kotyrba L, Mutch S, Abo M, McCorrister S, Westmacott G, Aldrovandi GM, Burgener A	Poster presentation
<i>Wednesday, 7 March</i>			
P1078	Randomized trial of safety of isoniazid preventive therapy during or after pregnancy	Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Onyango-Makumbi C, Chipato T, Masheto G, Shin K, Zimmer B, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A, for the IMPAACT P1078//TB APPRISE Study Team	Oral presentation, 11:45 am – 12:00 pm